Avicanna (TSE:AVCN)
TSX:AVCN
Want to see TSE:AVCN full AI Analyst Report?
AVCN Stock Chart & Stats
C$0.22
C$0.02(4.41%)
At close: 4:00 PM EST
C$0.22
C$0.02(4.41%)
Day’s Range― - ―
52-Week RangeC$0.11 - C$0.31
Previous CloseN/A
Volume8.50K
Average Volume (3M)55.79K
Market Cap
C$13.84M
Enterprise ValueC$15.35M
Total Cash (Recent Filing)C$372.10K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding125,791,870
10 Day Avg. Volume77,161
30 Day Avg. Volume55,794
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.08
Price to Sales (P/S)1.01
P/FCF Ratio-17.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginsSustained margin expansion to 53% indicates structurally stronger product economics and better cost control. Higher gross margins provide operating leverage, support reinvestment in R&D and commercialization, and materially improve the path to profitability even if revenue growth is gradual.
Debt-free, Repaired Balance SheetZero reported debt and positive equity materially reduce refinancing and interest-rate risk, improving financial flexibility. A repaired balance sheet supports multi-quarter execution, partner deals or licensing, and lowers the probability that short-term cash needs force dilutive financings.
Proprietary R&D, IP And Clinical EvidenceProprietary delivery platforms, granted patents and progressing trials create durable differentiation and potential commercialization exclusivity. Clinical and RWE data strengthen medical credibility, support premium positioning, and enable licensing or higher-margin pharma pathways over time.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow means the business continues to consume capital to run and scale. This structural cash burn increases reliance on external funding or asset monetization, which can dilute shareholders or constrain investment in commercialization and growth.
Flat Top-line GrowthStagnant revenue despite margin gains signals limited commercial traction or distribution constraints. Without sustained top-line growth, improved unit economics may not translate into sustainable operating profits, slowing scaling and limiting returns on R&D and commercial investments.
Regulatory And Commercialization UncertaintyDependence on regulatory shifts (e.g., U.S. rescheduling) and early-stage product launches creates timing and execution risk. Such structural uncertainties can delay market access, limit addressable markets, and require extended investment cycles before revenue and margin benefits are realized.
Avicanna News
AVCN FAQ
What was Avicanna’s price range in the past 12 months?
Avicanna lowest stock price was C$0.10 and its highest was C$0.31 in the past 12 months.
What is Avicanna’s market cap?
Avicanna’s market cap is C$13.84M.
When is Avicanna’s upcoming earnings report date?
Avicanna’s upcoming earnings report date is Aug 17, 2026 which is in 67 days.
How were Avicanna’s earnings last quarter?
Currently, no data Available
Is Avicanna overvalued?
According to Wall Street analysts Avicanna’s price is currently Overvalued.
Does Avicanna pay dividends?
Avicanna does not currently pay dividends.
What is Avicanna’s EPS estimate?
Avicanna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avicanna have?
Avicanna has 125,791,870 shares outstanding.
What happened to Avicanna’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Avicanna?
Currently, no hedge funds are holding shares in TSE:AVCN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avicanna
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses R&D and clinical trials, often undertaken in collaboration with Canadian academic and medical institutions. This effort has yielded around twenty commercialized products spanning four primary market categories. These offerings include medical and wellness items under the RHO Phyto brand, featuring cannabinoids such as CBD, CBG, and THC; CBD-infused topical and derma-cosmetic products marketed under the Pura H&W and Pura Earth labels; and bulk cannabis and hemp-derived raw materials like dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, and isolates, provided through the Aureus brand. Additionally, Avicanna is advancing a pharmaceutical pipeline focused on treatments for conditions including epidermolysis bullosa, dermatological ailments, chronic pain, and various neurological disorders. A notable research partnership with Dr. Christine Allen's Research Group is dedicated to developing a cannabinoid-based therapy for lung inflammation linked to COVID-19.
Technical Analysis
Charlotte's Web Holdings
―
MediPharm Labs
―
PharmaCielo
―
Cardiol Therapeutics
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---